SONOSCAPE(SZ:300633)2025-01-17 11:26Financial Projections - The estimated net profit attributable to shareholders for 2024 is projected to be between 136 million and 182 million CNY, representing a decline of 59.95% to 70.07% compared to the previous year[3]. - The estimated net profit after deducting non-recurring gains and losses is projected to be between 104.4 million and 150.4 million CNY, reflecting a decrease of 66.01% to 76.41% year-over-year[3]. Revenue Decline Factors - The decline in net profit is primarily due to reduced procurement activities for medical equipment in domestic healthcare institutions, leading to a decrease in domestic business revenue[5]. - Increased competition in the domestic medical device industry has resulted in a growing number of centralized procurement projects, causing a downward trend in product sales gross margin[6]. Strategic Investments - The company has maintained high strategic investment intensity, increasing support for new product lines and hiring various R&D and sales talents, resulting in a year-over-year increase in both sales and R&D expenses[6]. Non-Recurring Gains and Losses - The impact of non-recurring gains and losses on net profit attributable to the parent company is estimated to be 31.6 million CNY, primarily from government subsidies and financial product income, compared to 11.97 million CNY in the same period last year[6].